- Home
- BLTE
BLTE
Belite Bio Inc
as 04-18-2025 1:32pm EST
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.1B | IPO Year: | 2022 |
| Target Price: | $96.67 | AVG Volume (30 days): | 37.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $32.25 - $86.53 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Belite Bio Inc News
BLTE Breaking Stock News: Dive into BLTE Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Belite Bio Q4 Loss Widens
GlobeNewswire
a month ago
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
GlobeNewswire
a month ago
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
a month ago
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
2 months ago
Belite Bio to Participate in the Leerink Partners Global Healthcare Conference
MT Newswires
2 months ago
Belite Bio Shares Phase 3 Interim Results for its Stargardt Disease Trial
GlobeNewswire
2 months ago
Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects
MT Newswires
2 months ago
Belite Bio Signs Securities Purchase Deal for its American Depositary Shares, Warrants
Compare BLTE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BLTE Belite Bio Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.